Latest News and Press Releases

WALTHAM, Mass., March 17, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...

- Efficacy endpoints reordered and co-primary endpoints established -- Ongoing trial, if successful, expected to serve as single pivotal study for BLA submission - - Conference Call Scheduled for...

Review results of PATENCY-1, the Phase 3 trial of investigational vonapanitase Data on impact of fistula outcomes on Medicare costs WALTHAM, Mass., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Proteon...

- Trial Did Not Meet Primary Efficacy Endpoint - - Important Secondary and Tertiary Endpoint Data and Enrollment in Second Phase 3 Ongoing - - Conference Call Scheduled for 8:30 AM ET - WALTHAM,...

WALTHAM, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...

WALTHAM, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...

WALTHAM, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...

WALTHAM, Mass., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...

WALTHAM, Mass., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...

WALTHAM, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...